abstract |
The present invention provides multi-specific binding proteins that bind to the NKG2D receptor, CD16, and tumor-associated antigen selected from EGFR, HLA-E, CCR4, and PD-L1, as well as pharmaceutical compositions. and therapeutic methods useful for the treatment of cancer. |